As of 2026-08-28, PUMA BIOTECHNOLOGY, INC. (PBYI) trades at $9.24 against an EvidInvest fair-value range of $4.97–$11.32 (base estimate $7.97), built from 6 independent valuation methods on filed financial statements. The market price is 16% above the base estimate, so the models read the stock as fairly valued. Research, not investment advice.
Download the full PBYI valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.
PEG Ratio is not meaningful: Zero Growth
Interpretation
PEG = P/E ÷ Annual EPS Growth Rate (%). Peter Lynch's growth-adjusted value metric.
Interpretation
EV/EBITDA = Enterprise Value ÷ EBITDA. Capital-structure neutral — preferred by professional investors.
Interpretation
P/S = Market Cap ÷ Revenue. Useful for growth/unprofitable companies. SaaS/high-growth norms higher.
Interpretation
P/B = Price ÷ Book Value per Share. Essential for banks, REITs, and asset-heavy companies.
54.7% premium vs current price
Interpretation
√(22.5 × EPS × Book Value/Share) — Benjamin Graham's intrinsic value estimate.
-48.0% vs current price ($9.24)
✅ Competitive advantage likely
Greenwald EPV assumes zero future growth — this is the floor value of the business as a going concern.